Savara Inc.

SVRA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$5.37-0.92%

2026-09-18

Financials

Valuation Metrics

Savara Inc.'s Market Cap is $1.10B. At end of 2025 it was $1.34B. Ranked #2414 of 3,121 in US market (top 77%), #980 of 1,463 on NASDAQ (top 67%), #182 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$1.10B	US#2,414/3,121 Sec#182/266
Revenue	$0.00	US#2,889/3,121 Sec#196/266
Net Income	$-139M	US—/3,121 Sec—/266
Total Assets	$192M	US#3,002/3,121 Sec#248/266
Net Assets	$144M	US#2,758/3,121 Sec#207/266
Employees	70	US#2,679/3,121 Sec#197/266
Value
P/B	7.66x	US#2,504/3,121 Sec#181/266
FCF Yield	-10.06%	US—/3,121 Sec—/266
Profitability
ROE	-96.97%	US#2,787/3,121 Sec#200/266
ROA	-72.50%	US#3,037/3,121 Sec#242/266
Financial Health
Debt Ratio	33.74%	US#384/3,121 Sec#115/266
Total Debt	$30M	US#2,697/3,121 Sec#177/266
FCF	$-111M	US#2,649/3,121 Sec#151/266
Cash	$42M	US#2,655/3,121 Sec#237/266
Current Ratio	10.13x	US#252/3,121 Sec#79/266
Performance
1Y Return	49.17%	US#566/3,121 Sec#111/266
1M Return	-3.76%	US#833/3,121 Sec#84/266
From 52W High	-23.40%	US#1,668/3,121 Sec#126/266
1Y MDD	-31.99%	US#1,556/3,121 Sec#100/266
Trading
Volume	1,649,032 shares	US#1,276/3,121 Sec#136/266
Trading Value	$9M	US#2,581/3,121 Sec#215/266
Per Share
EPS	$-0.68	US—/3,121 Sec—/266
BPS	$0.70	US#2,736/3,121 Sec#212/266

Company Info

CEO Matthew Pauls

Employees 70

HQ Yardley, US

Website https://www.savarapharma.com

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.